Sequent Scientific Ltd — Profit & Loss Statement

₹188.78

+0.00%

Sequent Scientific Ltd Profit & Loss Statement (Annual)

Metric	2025	2024	2023	2022
Reconciled Cost Of Revenue	864.23 Cr	813.12 Cr	898.51 Cr	844.44 Cr
EBITDA	166.71 Cr	53.32 Cr	-52.25 Cr	117.98 Cr
EBIT	100.26 Cr	-8.22 Cr	-107.94 Cr	66.44 Cr
Net Interest Income	-58.03 Cr	-47.42 Cr	-34.31 Cr	-15.53 Cr
Interest Expense	55.96 Cr	46.42 Cr	29.72 Cr	13.51 Cr
Interest Income	2.72 Cr	0.67 Cr	1.21 Cr	0.24 Cr
Normalized Income	19.09 Cr	-21.97 Cr	-30.00 Cr	41.15 Cr
Net Income From Continuing And Discontinued Operation	21.88 Cr	-35.87 Cr	-121.16 Cr	40.95 Cr
Total Expenses	1.43K Cr	1.33K Cr	1.42K Cr	1.34K Cr
Rent Expense Supplemental	8.63 Cr	4.25 Cr	3.40 Cr	1.99 Cr
Diluted Average Shares	25.63 Cr	24.99 Cr	25.01 Cr	25.07 Cr
Basic Average Shares	24.94 Cr	24.86 Cr	24.85 Cr	24.74 Cr
Diluted EPS	0.85	-1.44	-4.88	1.63
Basic EPS	0.88	-1.44	-4.88	1.65
Diluted NI Availto Com Stockholders	21.88 Cr	-35.87 Cr	-121.16 Cr	40.95 Cr
Net Income Common Stockholders	21.88 Cr	-35.87 Cr	-121.16 Cr	40.95 Cr
Otherunder Preferred Stock Dividend	0.00	0.00	0.00	0.00
Net Income	21.88 Cr	-35.87 Cr	-121.16 Cr	40.95 Cr
Minority Interests	-10.38 Cr	-6.26 Cr	0.82 Cr	-3.81 Cr
Net Income Including Noncontrolling Interests	32.26 Cr	-29.61 Cr	-121.98 Cr	44.76 Cr
Net Income Continuous Operations	32.26 Cr	-29.61 Cr	-121.98 Cr	44.76 Cr
Tax Provision	12.05 Cr	-25.03 Cr	-15.68 Cr	8.17 Cr
Pretax Income	44.31 Cr	-54.65 Cr	-137.66 Cr	52.93 Cr
Other Non Operating Income Expenses	-12.48 Cr	-9.03 Cr	-12.35 Cr	-5.17 Cr
Special Income Charges	3.69 Cr	-19.89 Cr	-79.89 Cr	-0.55 Cr
Other Special Charges	-5.66 Cr	-3.15 Cr	16.96 Cr	0.18 Cr
Write Off	0.01 Cr	0.06 Cr	0.18 Cr	0.33 Cr
Impairment Of Capital Assets	0.28 Cr	0.16 Cr	0.16 Cr	0.03 Cr
Restructuring And Mergern Acquisition	1.68 Cr	22.81 Cr	42.18 Cr	0.00
Net Non Operating Interest Income Expense	-58.03 Cr	-47.42 Cr	-34.31 Cr	-15.53 Cr
Total Other Finance Cost	4.79 Cr	1.66 Cr	5.80 Cr	2.27 Cr
Interest Expense Non Operating	55.96 Cr	46.42 Cr	29.72 Cr	13.51 Cr
Interest Income Non Operating	2.72 Cr	0.67 Cr	1.21 Cr	0.24 Cr
Operating Income	119.03 Cr	37.02 Cr	0.28 Cr	67.39 Cr
Operating Expense	563.72 Cr	516.16 Cr	519.48 Cr	498.34 Cr
Other Operating Expenses	119.58 Cr	113.58 Cr	120.66 Cr	138.38 Cr
Depreciation And Amortization In Income Statement	66.45 Cr	61.54 Cr	55.69 Cr	51.54 Cr
Amortization	11.80 Cr	10.56 Cr	10.50 Cr	7.40 Cr
Depreciation Income Statement	54.65 Cr	50.98 Cr	45.20 Cr	44.14 Cr
Selling General And Administration	89.39 Cr	83.95 Cr	82.16 Cr	77.71 Cr
Selling And Marketing Expense	34.24 Cr	28.59 Cr	28.13 Cr	27.68 Cr
General And Administrative Expense	55.15 Cr	55.36 Cr	54.03 Cr	50.03 Cr
Rent And Landing Fees	8.63 Cr	4.25 Cr	3.40 Cr	1.99 Cr
Gross Profit	682.75 Cr	553.18 Cr	519.76 Cr	565.74 Cr
Cost Of Revenue	864.23 Cr	813.12 Cr	898.51 Cr	844.44 Cr
Total Revenue	1.55K Cr	1.37K Cr	1.42K Cr	1.41K Cr
Operating Revenue	1.55K Cr	1.37K Cr	1.42K Cr	1.41K Cr
Tax Effect Of Unusual Items	1.04 Cr	-5.96 Cr	-9.09 Cr	-0.04 Cr
Tax Rate For Calcs	0.27	0.30	0.11	0.15
Normalized EBITDA	162.88 Cr	73.17 Cr	7.19 Cr	118.21 Cr
Total Unusual Items	3.84 Cr	-19.85 Cr	-59.43 Cr	-0.23 Cr
Total Unusual Items Excluding Goodwill	3.84 Cr	-19.85 Cr	-79.84 Cr	-0.23 Cr
Net Income From Continuing Operation Net Minority Interest	21.88 Cr	-35.87 Cr	-121.16 Cr	40.95 Cr
Reconciled Depreciation	66.45 Cr	61.54 Cr	55.69 Cr	51.54 Cr

All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.

More on Sequent Scientific Ltd

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Pharmaceuticals Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.